

Request title: Prostate Cancer Drugs

Date of Response: 07th December 2016

Further to your Freedom of Information request, the Trust has answered your questions in the order they appear in your request.

Request and Reply

1. How many patients with Advanced Prostate Cancer have received

Abiraterone (Zytiga)	54
Cabazitaxel (Jevtana)	12
Docetaxel (Taxotere)	30
Enzalutamide (Xtandi)	72
Radium-223 (Xofigo)	0
Bicalutamide (Casodex)	0

2. How many patients with differentiated non-medullary thyroid cancer have received

Axitinib (Inlyta)	0
Cabozantinib [Cometriq]	0
Pazopanib (Votrient)	0
Sorafenib (Nexavar)	0
Sunitinib (Sutent)	0
Vandetanib [Caprelsa]	0

The Trust can confirm that no chemotherapy regimes have been released for this diagnosis

3. How many patients with Gastrointestinal Stromal Tumours have received

Dasatinib (Sprycel)	0
Imatinib (Glivec)	12
Nilotinib (Tasigna)	0
Pazopanib (Votrient)	0
Regorafenib (Stivarga)	0
Sorafenib (Nexavar)	0
Sunitinib (Sutent)	0

The Trust can confirm that GIST patients only receive Glivec at RD&E and no other diagnosis currently use this.